Physician profile
Harmandeep Singh
NPI 1619110525
$6,694.16
in general payments reported to CMS, 2019-2025
20 companies · $543 in 2025
The $543 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,568 · 2020: $124 · 2021: $142 · 2022: $2,047 · 2023: $822 · 2024: $447 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,509.12 | 2019 | |
| Silk Road Medical, INC. | $1,235.33 | 2022 | |
| Medtronic, INC. | $1,014.24 | 2021-2025 | Endurant Iis, Signia |
| Medtronic Vascular, INC. | $654.58 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $556.14 | 2022-2023 | Viabahn Endoprosthesis With Propaten Bioactive Surface, Gore Viabahn Endoprosthesis With Heparin |
| Boston Scientific Corporation | $550.94 | 2019-2025 | Eluvia, Complex Helical - 18, Jetstream Sc |
| Shockwave Medical, INC | $440.71 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lemaitre Vascular, INC. | $265.98 | 2019-2023 | Artegraft Vascular Graft |
| Avanos Medical | $115.28 | 2019 | |
| Penumbra, INC. | $105.00 | 2023 | Ruby Coil |
| Janssen Biotech, INC. | $33.14 | 2023 | Tremfya |
| Terumo Medical Corporation | $32.51 | 2019 | |
| Hologic Sales and Service, LLC | $30.67 | 2024 | Trident Specimen Radiography System, Localizer |
| Abbvie INC. | $30.47 | 2025 | |
| Amgen INC. | $25.31 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.03 | 2025 | Verquvo |
| Smith+Nephew, INC. | $21.89 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $17.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.60 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmandeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.